| Project/Area Number |
21591685
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
SEKI Naoko 久留米大学, 医学部, 助教 (40226634)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TOH Uhi 久留米大学, 医学部, 講師 (60268901)
FUJII Teruhiko 久留米大学, 医学部, 准教授 (50199288)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
YAMANA Hideaki 久留米大学, 医学部, 教授 (30140669)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 癌 / 免疫 / 乳腺外科学 |
|---|
| Research Abstract |
The transcription factor forkhead box protein3(FOXP3) is highly expressed not only in regulatory T cells(Tregs), but also in tumor cells. FOXP3 possesses a tumor-enhancing role through Tregs and their effect on tumor tolerance, but also suppresses carcinogenesis as a potent repressor of several oncogenes. In this study, we immunohistochemically studied the prognostic significance of FOXP3 expression both in tumor cells and tumor infiltrates of lymphocytes in breast cancer patients.
Of 100 tumor specimens with primary invasive breast carcinoma(including 23 HER2-overexpressing specimens), 63% and 57% were evaluated as FOXP+tumor cells and high infiltrate of FOXP3+lymphocytes, respectively. FOXP3 expression in tumor cells did not show prognostic significance, while FOXP3+lymphocytes was significantly associated with poor overall survival(OS ; n=98, log-rank test p=0.008). The heterogeneous subcellular localization of FOXP3 was observed in tumor cells(cytoplasm, 31%; nucleus, 26%; and both, 6%), and interestingly, cytoplasmic and nuclear FOXP3 were associated with poor(p=0.058) and improved(p=0.016) OS, respectively. These findings indicate that FOXP3 expression in both lymphocytes and tumor cells could be a prognostic marker for breast cancer. FOXP3 in tumor cells might have distinct biological activities and prognostic values according to the localization, which would be help identify appropriate therapy for the patients.
|
